Development of [(225)Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy which may benefit from radioimmunotherapy. Previously, [(177)Lu]Lu-DOTA-C595 has been developed as a beta-emitting radioimmunoconjugate to target cancer-specific mucin 1 epitopes (MUC1-CE) overexpressed on PDAC. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hull, Ashleigh, Hsieh, William, Borysenko, Artem, Tieu, William, Bartholomeusz, Dylan, Bezak, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484829/
https://www.ncbi.nlm.nih.gov/pubmed/37679594
http://dx.doi.org/10.1186/s41181-023-00209-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484829/
https://www.ncbi.nlm.nih.gov/pubmed/37679594
http://dx.doi.org/10.1186/s41181-023-00209-z

Ejemplares similares